"uuid:ID","instanceType","versionIdentifier","rationale","id"
"3e768505-ebe6-49dc-aa88-8a9f99107d68","StudyVersion","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
